Blood monitoring,
reimagined

Introducing Sight OLO ® brought to you by AASPIRE 
Fast, convenient, and accurate blood monitoring at the point of care

AA-Pharma is proud to partner with Sight Diagnostics® to exclusively bring OLO to patients on AA-Clozapine.

Reliable blood monitoring at your fingertips

OLO is a high-performance CBC analyzer. It delivers lab-grade results in minutes from 2 drops of blood obtained from 1 finger prick sample.¹

OLO is licensed in Canada for performing CBC tests at the point of care.*³

OLO is licenced in Canada for performing CBC tests at the point of care.*3

OLO simplifies required blood monitoring with:

Point-of-care use

  • On-site blood monitoring means real-time clinical decisions, with less hassle for patients
Icon of a finger prick

Direct-from-finger prick testing

  • Quick and less invasive than venipuncture¹
  • Removes one of the most common barriers to clozapine therapy
icon of 2 blood drops

Just 2 drops of blood (27 μL)1

  • Requires only 5% of the minimum blood volume needed for traditional lab-based testing methods¹
icon of a stop watch

Rapid results

  • Actionable results are ready in minutes, enabling faster treatment decisions for optimal patient care

Results can be seamlessly and securely shared with AASPIRE and the patient’s electronic record to ensure ongoing monitoring of patients on clozapine therapy.

AAspire Logo

Results can be seamlessly and securely shared with AASPIRE and the patient’s electronic record to ensure ongoing monitoring of patients on clozapine therapy.

Proven lab-grade results without the lab

OLO provides 5-part CBC results with 19 parameters, including white blood cell (WBC) count and absolute neutrophil count (ANC).1

Cutting-edge digital microscopy and artificial intelligence algorithms combine to deliver CBC results that match best-in-class laboratory equipment.1

blood cell

Better patient experience, better patient care in 3 easy steps1

Prepare finger prick sample

Analyze with OLO

View results

Works for patients

Testing is less painful, non-invasive, and convenient, reducing the impact of required blood monitoring on the quality of life for patients on clozapine.  

Works for clinicians

Reliable, real-time results enable quick and informed treatment decisions.

Sight OLO brought to you by AASPIRE. It just works.

For more information about blood monitoring with OLO, talk to our team: customerservice@aapharma.ca

Sight OLO brought to you by AASPIRE. It just works.

For more information about blood monitoring with OLO, talk to our team: customerservice@aapharma.ca

Just 1 finger prick and 2 drops of blood

See how OLO makes it possible.
DOWNLOAD BROCHURE >

Just 1 finger prick and 2 drops of blood

See how OLO makes it possible.
DOWNLOAD BROCHURE >

Intended for audiences in Canada only.

For full indications for use and safety information, please refer to the Quality and Compliance page at
https://www.sightdx.com/quality-and-compliance

* Sight OLO is licensed by Health Canada as a Class III device (Licence No.: 106263).

CBC, complete blood count.

References:

1. Sight Diagnostics data on file. 2. Sight OLO. Health Canada Medical Device Licence 106263. Issued November 2, 2021. 3. Sight OLO-U1 Operator’s Manual. Sight Diagnostics. April 2021. 

Sight OLO is a registered trademark of Sight Diagnostics. 

© 2021 Sight Diagnostics Ltd. All rights reserved.

This site uses cookies

We use cookies to provide a smoother user experience while you are visiting our site. We do not store or share any of your personal information.